Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 13/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.42 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL1634342 | 0.97 | DRD3 (0.47) | DRD3CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL1633684 | 0.86 | CYP1A2 (0.47) | DRD3KIF11GRIN2DGRIN1GRIN2A | |
| Bromide SCHEMBL1634846 | 0.83 | CYP1A2 (0.44) | DRD3KIF11GRIN2DGRIN1GRIN2A | |
| Bromide SCHEMBL1634339 | 0.82 | KIF11 (0.38) | DRD3CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5088090 | 0.73 | CHRM1 (0.68) | DRD3CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL4550704 | 0.73 | CYP1A2 (0.70) | DRD3CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL6657008 | 0.73 | CYP1A2 (0.70) | DRD3CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL656271 | 0.72 | ESR1 (0.49) | DRD3CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL1869110 | 0.71 | HDAC1 (0.59) | DRD3CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL7168982 | 0.71 | MME (0.45) | HDAC1HDAC2KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932290-B2 | Method for the treatment of metabolic disorders | WELLSTAT BIOLOGICS CORPORATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20100087541-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-04-08 | — | — | US | disclosed |
| US-7615575-B2 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-11-10 | — | — | US | disclosed |
| US-7605181-B2 | Method for the treatment of metabolic disorders | Wellstat Therapeutics Orporation (US) | 2009-10-20 | — | — | US | disclosed |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087541-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | DRD3 2579/4885CHRM1 157/4885AKR1A1 161/4885 |
| US-20080015254-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | CPT1B, FABP1, CPT1A | DRD3 2579/4885CHRM1 157/4885AKR1A1 161/4885 |
| US-20060247309-A1 | Compounds for the treatment of metabolic disorders | CPT1B, CPT1A, FABP1 | DRD3 3928/4885CHRM1 488/4885AKR1A1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.